Global Ocular Gene Therapy Market Growth (Status and Outlook) 2024-2030

Global Ocular Gene Therapy Market Growth (Status and Outlook) 2024-2030

The global Ocular Gene Therapy market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LPI (LP Information)' newest research report, the “Ocular Gene Therapy Industry Forecast” looks at past sales and reviews total world Ocular Gene Therapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Ocular Gene Therapy sales for 2023 through 2029. With Ocular Gene Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Ocular Gene Therapy industry.

This Insight Report provides a comprehensive analysis of the global Ocular Gene Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Ocular Gene Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Ocular Gene Therapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ocular Gene Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ocular Gene Therapy.

United States market for Ocular Gene Therapy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Ocular Gene Therapy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Ocular Gene Therapy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Ocular Gene Therapy players cover AbbVie, MeriaGTx, Regenxbio, GenSight Biologics, Astellas, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Ocular Gene Therapy market by product type, application, key players and key regions and countries.

Segmentation by Type:
Gene Replacement Technology
Gene Editing Technology
Others

Segmentation by Application:
Hospitals
Diagnostics Centers
Research Institutes

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Gene Replacement Technology
Gene Editing Technology
Others

Segmentation by Application:
Hospitals
Diagnostics Centers
Research Institutes

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AbbVie
MeriaGTx
Regenxbio
GenSight Biologics
Astellas
Neurophth Therapeutics
Innostellar Biotherapeutics
Exegenesis Bio
Zhongyin Technology

Please note: The report will take approximately 2 business days to prepare and deliver.